Navigating Semaglutide and Omeprazole: What You Need to Know

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Omeprazole is one of the few oral drugs that has actually been studied alongside semaglutide, and the finding is reassuring rather than alarming: the Rybelsus and Ozempic tablets prescribing information reports that no clinically significant differences in semaglutide pharmacokinetics were observed when it was used concomitantly with omeprazole. The real question with this pair is not whether one blocks the other. It is that both act on the stomach, both can produce overlapping digestive symptoms, and the labels handle oral co-medication differently depending on which semaglutide product you are taking.

What the Interaction Studies Found

Novo Nordisk ran a programme of drug interaction trials for oral semaglutide precisely because delayed gastric emptying could plausibly change how other oral drugs are absorbed. Omeprazole was one of the agents tested, and the label reports no clinically significant difference in semaglutide pharmacokinetics when the two were used together.

The same section reports no clinically significant pharmacokinetic differences for lisinopril, S-warfarin, R-warfarin, metformin, digoxin, ethinyl estradiol, levonorgestrel, furosemide or rosuvastatin. The one exception worth naming is levothyroxine, where total thyroxine exposure increased by 33% following a single 600 mcg dose given with semaglutide tablets.

Semaglutide also has very low potential to inhibit or induce CYP enzymes or to inhibit drug transporters, which is why the interaction profile is dominated by gastric emptying effects rather than by classical metabolic interactions.

The Two Labels Are Not Interchangeable Here

Ozempic section 7.2 states that the drug causes a delay of gastric emptying and thereby has the potential to impact absorption of concomitantly administered oral medications, notes that semaglutide did not affect absorption to any clinically relevant degree in clinical pharmacology trials, and concludes that caution should nonetheless be exercised.

Wegovy section 7.2 goes further. It directs prescribers to monitor the effects of oral medications administered concomitantly and to consider increased clinical or laboratory monitoring for medications with a narrow therapeutic index or that require clinical monitoring. The Rybelsus and Ozempic tablets label carries similar monitoring language.

That difference is easy to miss and worth flagging to your prescriber, because "use with caution" and "consider increased clinical or laboratory monitoring" describe different levels of active follow-up.

Why the Symptoms Can Look the Same

The most common adverse reactions reported in at least 5% of Ozempic-treated patients are nausea, vomiting, diarrhea, abdominal pain and constipation. Proton pump inhibitors are also associated with abdominal pain, diarrhea, nausea and flatulence.

When both are started or escalated around the same time, attributing a new symptom to the right drug becomes genuinely difficult. Staggering changes, rather than altering two things at once, is the usual clinical approach — but sequencing is a decision for your prescriber, not something to improvise.

The Wegovy label added a Severe Gastrointestinal Adverse Reactions subsection in its 10/2025 revision, and semaglutide is not recommended in patients with severe gastroparesis. If reflux symptoms are the reason you are on a proton pump inhibitor, that history is relevant context for the conversation.

Oral Semaglutide Has Administration Requirements That Injections Do Not

The Rybelsus and Ozempic tablets label contains specific directions about how the tablets are taken relative to food, water and other oral medications, and it also states that Rybelsus and Ozempic tablets are not substitutable on a milligram-to-milligram basis.

Those directions exist because oral semaglutide absorption is genuinely sensitive to conditions in the stomach. That is exactly why a second gastric-acting drug in the same regimen is worth raising explicitly rather than assuming it is inconsequential.

The specifics belong on your pharmacy label and in your prescriber’s instructions. This article deliberately does not restate an administration schedule, because getting it slightly wrong in a general context is worse than sending you to the source that applies to your prescription.

Long-Term Proton Pump Inhibitor Use Raises Its Own Questions

Prolonged proton pump inhibitor therapy has been associated in the literature with reduced absorption of vitamin B12, magnesium, calcium and iron. Semaglutide independently reduces total food intake by suppressing appetite.

Those two effects push in the same direction on micronutrient status. That is a reason for periodic laboratory review during combined therapy rather than a reason to avoid either drug, and the decision about what to check and when is a clinical one.

It is also worth asking, periodically, whether the proton pump inhibitor is still needed. Many people remain on acid suppression long after the indication that started it has resolved, and deprescribing is a legitimate conversation to raise.

What to Bring to the Appointment

A complete list of everything you take, including over-the-counter acid suppression, supplements and anything with a narrow therapeutic index such as levothyroxine, warfarin or antiepileptics. Those are the drugs the Wegovy label singles out for increased monitoring.

A note of which semaglutide product you are on. Ozempic, Wegovy, Rybelsus and Ozempic tablets have different indications and different section 7.2 language, and compounded semaglutide is a separate category again with no FDA-reviewed labeling of its own.

And a symptom timeline. Knowing whether the nausea started before or after the acid suppression changed is often the single most informative piece of data in the room.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Does omeprazole reduce how well semaglutide works?

The Rybelsus and Ozempic tablets prescribing information reports that no clinically significant differences in semaglutide pharmacokinetics were observed when it was used concomitantly with omeprazole. That is a direct interaction finding from the label. It does not remove the need for your prescriber to review the combination in the context of everything else you take.

Which oral drugs need extra monitoring with semaglutide?

The Wegovy label directs prescribers to consider increased clinical or laboratory monitoring for oral medications with a narrow therapeutic index or that require clinical monitoring, because semaglutide delays gastric emptying. The one measured exception in the interaction programme was levothyroxine, where total thyroxine exposure increased 33% after a single dose given with semaglutide tablets.

Why do the Ozempic and Wegovy labels say different things?

They are separate applications with separate labeling. Ozempic section 7.2 advises that caution should be exercised with concomitant oral medications. Wegovy section 7.2 additionally instructs prescribers to monitor the effects of oral medications and to consider increased clinical or laboratory monitoring for narrow-therapeutic-index drugs. The two sections are not interchangeable.

Can I stop my proton pump inhibitor once I start semaglutide?

That is a decision for your prescriber. Semaglutide slows gastric emptying and can worsen reflux in some people, so stopping acid suppression is not automatically appropriate. It is reasonable to ask periodically whether the proton pump inhibitor is still indicated, since many people remain on long-term acid suppression after the original reason has resolved.

Should I be worried about nutrient absorption on both drugs?

It is a fair question to raise. Long-term proton pump inhibitor use has been associated in the literature with reduced absorption of vitamin B12, magnesium, calcium and iron, and semaglutide independently reduces total food intake through appetite suppression. Those effects point the same way, which is a reason for periodic laboratory review rather than a reason to avoid either medication.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.